Supplementary Figure 5 from Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer Cells

Yang, Chunsong; Wierbiłowicz, Krzysztof; Dworak, Natalia M.; Bae, Song Yi; Tengse, Sachi B.; Abianeh, Nicki; Drake, Justin M.; Abbas, Tarek; Ratan, Aakrosh; Wotton, David; Paschal, Bryce M.

doi:10.1158/2767-9764.22644771.v1

Supplementary Figure 5 from Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer Cells

journal contribution

posted on 2023-04-17, 14:20 authored by Chunsong Yang, Krzysztof Wierbiłowicz, Natalia M. Dworak, Song Yi Bae, Sachi B. Tengse, Nicki Abianeh, Justin M. Drake, Tarek Abbas, Aakrosh Ratan, David Wotton, Bryce M. Paschal

FACS analysis of NCI-H660 cells for detection of necrosis and apoptosis

Funding

HHS | NIH | National Cancer Institute (NCI)

History

ARTICLE ABSTRACT

RBN2397 is a potent and selective inhibitor of PARP7 that reduces the growth of prostate cancer cells, including a model for treatment-emergent neuroendocrine prostate cancer. RBN2397 induces PARP7 trapping on chromatin, suggesting its mechanism of action might be similar to clinically used PARP1 inhibitors.

Usage metrics

Keywords

Biochemistry Small Molecule Agents Genitourinary Cancers Prostate cancer Gene Regulation Inducible gene expression Drug Targets Drug Mechanisms

Licence

CC BY

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Supplementary Figure 5 from Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer Cells

Funding

HHS | NIH | National Cancer Institute (NCI)

History

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports